pdlink.org
One-year Results in 2 Given Gene Therapy at Low Dose Showing Promise, Axovant Reports - PDlink
Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapy’s developer, said in a release. These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between …